Combination therapies for systemic sclerosis

Springer Seminars in Immunopathology

Volumn 23, Issue 1-2, 2001, Pages 109-129

  Denton, C P ^a   Black, C M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; ANTIOXIDANT; AUTOANTIBODY; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HALOFUGINONE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LANSOPRAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PROSTACYCLIN DERIVATIVE; PSORALEN DERIVATIVE; QUINAPRIL; RELAXIN; TACROLIMUS; THYMOCYTE ANTIBODY; VASODILATOR AGENT; WARFARIN;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DRUG INDUCED DISEASE; ENTEROPATHY; FIBROSING ALVEOLITIS; FIBROSIS; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MORPHEA; MYOSITIS; OPPORTUNISTIC INFECTION; OVARY DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SCLERODERMA; SYSTEMIC SCLEROSIS;

ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PENICILLAMINE; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 0034928981     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002810100058     Document Type: Review

References (68)

1. How can treatment of systemic sclerosis be improved?
2. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
3. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
4. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study
5. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial
6. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis
7. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis
8. Anti-RNA polymerases and other auto-antibody specificities in systemic sclerosis
9. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis
10. Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal
11. The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectases in patients with scleroderma
12. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
13. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation
14. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients
15. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis
16. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
17. Comparison of Doppler-echocardiography and right heart catheterisation to assess pulmonary hypertension in systemic sclerosis
18. Acute renal failure occurring in scleroderma treated with cyclosporin A: A report of three cases
19. Related Articles Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
20. Etanercept as treatment for diffuse scleroderma: A pilot study
21. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis
22. Intensive immunosuppression and stem cell transplantation in scleroderma
23. Efficacy of cyclosporin A in systemic sclerosis
24. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma
25. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial
26. Pulmonary involvement in systemic sclerosis: The detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance
27. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis
28. Prevalence of systemic sclerosis in a semi-rural population
29. Circulating type I collagen degradation products: A new serum marker for clinical severity in patients with scleroderma?
30. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine
31. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice
32. Management of severe scleroderma with long-term extracorporeal photopheresis
33. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone
34. The watermelon stomach: Long-term outcome in patients treated with Nd:YAG laser therapy
35. Severe involvement of the conduction system in a patient with sclerodermal heart disease. An electrophysiological study
36. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting enzyme blockade
37. Early pulmonary hypertension in systemic sclerosis: Risk of progression and consequences for survival
38. Pilot study of antithymocyte globulin in systemic sclerosis
39. Connective tissue disease registries
40. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen
41. A disease severity scale for systemic sclerosis: Development and testing
42. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma
43. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis
44. Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients
45. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma - Preliminary analysis
46. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis
47. An open trial of FK506 in the treatment of early diffuse scleroderma
48. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis
49. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial
50. QT interval and QT dispersion in systemic sclerosis (scleroderma)
51. Assessment of functional ability in patients with scleroderma: A proposed new disability assessment instrument
52. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study
53. The palpable tendon friction rub: An important physical examination finding in patients with systemic sclerosis
54. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
55. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time
56. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: A pilot study
57. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma
58. Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases
59. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo
60. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial
61. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease
62. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis
63. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
64. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions
65. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
66. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study
67. Nifedipine in primary Raynaud's phenomenon and in scleroderma: Oral versus sublingual hemodynamic effects
68. Cyclosporin A treatment of systemic sclerosis